BAX logo

BAXTER INTERNATIONAL INC

BAXNYSE
πŸ† #679 by market capEarnings Oct 29US Equity
$25.46β–² $0.54 (+2.17%)
πŸŒ™ After hours$26.00β–² 2.12%Regular close Β· extended-hours price shown
πŸ””
Track BAX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.2%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$13.16B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
5.4%
Slowing
πŸ“ŠGross Margin
30.7%
Moderate
πŸ’΅FCF Margin
7.1%
Moderate
βš–οΈP/S Ratio
1.1x
Cheap
Otter Score
76
Strong
No chart data available for BAX.

Trading Snapshot

Day Range
$24.93 – $26.02
52-Week Range
$15.73 – $30.00
Volume (shares)
12,433,170
Avg Volume (shares)
β€”
Shares Outstanding
517.0M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$11.24B
Last Q Revenue
$2.96B
P/E Ratio
β€”
P/S Ratio
1.1x
EPS (TTM)
$-2.07
Dividend Yield
1.41%
Dilution (1yr)
+0.8%
BAX logo

BAXTER INTERNATIONAL INC

BAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$11.2Bβ–² +5.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
30.1%β–Ό βˆ’19.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$308Mβ–Ό βˆ’2300.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$323Mβ–Ό βˆ’42.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
514.0Mβ–² +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$7.8Bβ–² +$3.9B YoY
StockOtter Β· stockotter.space

About BAXTER INTERNATIONAL INC

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

Zacks Investment ResearchΒ·2d ago

Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?

Baxter International Inc.Β BAX is scheduled to releaseΒ third-quarter 2026 resultsΒ on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.

Defense WorldΒ·12d ago

20,728 Shares of Baxter International Inc. $BAX Acquired by Cohen Klingenstein LLC

Cohen Klingenstein LLC acquired a new position in shares of Baxter International Inc. (NYSE: BAX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund a

Seeking AlphaΒ·15d ago

Baxter International: The Vantive Transition Complicates Margin Recovery

Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions fac

Defense WorldΒ·17d ago

Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of

Business WireΒ·21d ago

Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m.

Zacks Investment ResearchΒ·22d ago

Are Investors Undervaluing Baxter International (BAX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and